Intestinal transport as a potential determinant of drug bioavailability

Current Clinical Pharmacology

Volumn 8, Issue 3, 2013, Pages 247-255

  Nauli, Andromeda M ^a   Nauli, Surya M ^b  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Absorption; Chylomicron; Enterohepatic; Fat; First pass effect; Lipid; Lymph; Portal

Indexed keywords

2ALPHA, 3ALPHA EPITHIO 5 ANDROSTAN 17 ONE; 4,7BETA DIMETHYL 4 AZACHOLESTAN 3 ONE; 5ALPHA ANDROST 2 EN 17 ONE; CL 976; COLECALCIFEROL; CP 524 515; CP 532 623; CYCLOSPORIN A; DEHYDROTESTOSTERONE 17BETA METHOXYCYCLOPENTYL ETHER; DELTA 4 ANDROSTAN 17BETA METHOXYCYCLOPENTYL ETHER; DRUG; EPITIOSTANOL; ETRETINATE; HALOFANTRINE; HEXACHLOROBENZENE; ISOTRETINOIN; LIPOPHILIC AGENT; LU 28 179; MEPITIOSTANE; MEPITIOSTANEOLEFIN; ONTAZOLAST; PENCLOMEDINE; SIRAMESINE; TEMAROTENE; TESTOSTERONE; TESTOSTERONE 17BETA METHOXYCYCLOPENTYL ETHER; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ARTICLE; DRUG BIOAVAILABILITY; DRUG UPTAKE; INTESTINE ABSORPTION; INTESTINE CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; LIVER; LYMPHATIC SYSTEM; PHARMACEUTICAL PREPARATIONS; PORTAL SYSTEM; SOLUBILITY;

EID: 84882796069     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308030012     Document Type: Article

References (82)

1. Khoo SM, Edwards GA, Porter CJ, Charman WN. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci 2001; 90(10): 1599-607.
2. Shackleford DM, Faassen WA, Houwing N, et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther 2003; 306(3): 925-33.
3. Trevaskis NL, Shackleford DM, Charman WN, et al. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm Res 2009; 26(6): 1486-95.
4. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 2008 17; 60(6): 702-16.
5. Yanez JA, Wang SW, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev 2011; 63(10-11): 923-42.
6. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6(3): 231-48.
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
8. Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 2008; 7(3): 205-20.
9. Katsura T, Inui K. Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab Pharmacokinet 2003; 18(1): 1-15.
10. Altmann SW, Davis HR, Jr., Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303(5661): 1201-4.
11. Nauli AM, Nassir F, Zheng S, et al. CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology 2006; 131(4): 1197-207.
12. Hofmann AF, Borgstrom B. Physico-chemical state of lipids in intestinal content during their digestion and absorption. Fed Proc 1962; 21: 43-50.
13. Wilson FA, Sallee VL, Dietschy JM. Unstirred water layers in intestine: rate determinant of fatty acid absorption from micellar solutions. Science 1971; 174(4013): 1031-3.
14. Nassir F, Wilson B, Han X, Gross RW, Abumrad NA. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J Biol Chem 2007; 282(27): 19493-501.
15. Porter HP, Saunders DR, Tytgat G, Brunser O, Rubin CE. Fat absorption in bile fistula man. A morphological and biochemical study. Gastroenterology 1971; 60(6): 1008-19.
16. van den Bosch H, Postema NM, de Haas GH, van Deenen LL. On the positional specificity of phospholipase A from pancreas. Biochim Biophys Acta 1965; 98(3): 657-9.
17. Mattson FH, Volpenhein RA. The Digestion and Absorption of Triglycerides. J Biol Chem 1964; 239: 2772-7.
18. Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol 2002; 64: 635-61.
19. Porter CJ, Charman SA, Charman WN. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J Pharm Sci 1996; 85(4): 351-6.
20. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 2006; 109(1-2): 137-61.
21. Strong HA, Oates J, Sembi J, Renwick AG, George CF. Role of the gut flora in the reduction of sulfinpyrazone in humans. J Pharmacol Exp Ther 1984; 230(3): 726-32.
22. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300(3): 1036-45.
23. Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 2004; 5(6): 483-505.
24. McDonald GB, Saunders DR, Weidman M, Fisher L. Portal venous transport of long-chain fatty acids absorbed from rat intestine. Am J Physiol 1980; 239(3): G141-50.
25. McDonald GB, Weidman M. Partitioning of polar fatty acids into lymph and portal vein after intestinal absorption in the rat. Q J Exp Physiol 1987; 72(2): 153-9.
26. Jandacek RJ, Rider T, Yang Q, Woollett LA, Tso P. Lymphatic and portal vein absorption of organochlorine compounds in rats. Am J Physiol Gastrointest Liver Physiol 2009; 296(2): G226-34.
27. Van Veld PA, Vetter RD, Lee RF, Patton JS. Dietary fat inhibits the intestinal metabolism of the carcinogen benzo[a]pyrene in fish. J Lipid Res 1987; 28(7): 810-7.
28. Vetter RD, Carey MC, Patton JS. Coassimilation of dietary fat and benzo(a)pyrene in the small intestine: an absorption model using the killifish. J Lipid Res 1985; 26(4): 428-34.
29. Nordskog BK, Phan CT, Nutting DF, Tso P. An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev 2001; 50(1-2): 21-44.
30. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009; 296(6): E1183-94.
31. Storch J, Thumser AE. The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 2000; 1486(1): 28-44.
32. Lowe JB, Sacchettini JC, Laposata M, McQuillan JJ, Gordon JI. Expression of rat intestinal fatty acid-binding protein in Escherichia coli. Purification and comparison of ligand binding characteristics with that of Escherichia coli-derived rat liver fatty acid-binding protein. J Biol Chem 1987; 262(12): 5931-7.
33. Richieri GV, Ogata RT, Kleinfeld AM. Equilibrium constants for the binding of fatty acids with fatty acid-binding proteins from adipocyte, intestine, heart, and liver measured with the fluorescent probe ADIFAB. J Biol Chem 1994; 269(39): 23918-30.
34. Baier LJ, Bogardus C, Sacchettini JC. A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells. J Biol Chem 1996; 271(18): 10892-6.
35. Vassileva G, Huwyler L, Poirier K, Agellon LB, Toth MJ. The intestinal fatty acid binding protein is not essential for dietary fat absorption in mice. FASEB J 2000; 14(13): 2040-6.
36. Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 2006; 44(5): 1191-205.
37. Lagakos WS, Gajda AM, Agellon L, et al. Different functions of intestinal and liver-type fatty acid-binding proteins in intestine and in whole body energy homeostasis. Am J Physiol Gastrointest Liver Physiol 2011; 300(5): G803-14.
38. Trevaskis NL, Nguyen G, Scanlon MJ, Porter CJ. Fatty acid binding proteins: potential chaperones of cytosolic drug transport in the enterocyte? Pharm Res 2011; 28(9): 2176-90.
39. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV, Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 2008; 49(11): 2283-301.
40. Cao J, Hawkins E, Brozinick J, et al. A predominant role of acyl-CoA: monoacylglycerol acyltransferase-2 in dietary fat absorption implicated by tissue distribution, subcellular localization, and upregulation by high fat diet. J Biol Chem 2004; 279(18): 18878-86.
41. Cases S, Smith SJ, Zheng YW, et al. Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998; 95(22): 13018-23.
42. Shi Y, Cheng D. Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol Endocrinol Metab 2009; 297(1): E10-8.
43. Cao J, Burn P, Shi Y. Properties of the mouse intestinal acyl-CoA: monoacylglycerol acyltransferase, MGAT2. J Biol Chem 2003; 278(28): 25657-63.
44. Cao J, Cheng L, Shi Y. Catalytic properties of MGAT3, a putative triacylgycerol synthase. J Lipid Res 2007; 48(3): 583-91.
45. Buhman KK, Smith SJ, Stone SJ, et al. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002; 277(28): 25474-9.
46. Ohashi K, Ishibashi S, Osuga J, et al. Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. J Lipid Res 2000; 41(8): 1199-204.
47. Jiang ZG, Liu Y, Hussain MM, Atkinson D, McKnight CJ. Reconstituting initial events during the assembly of apolipoprotein B-containing lipoproteins in a cell-free system. J Mol Biol 2008; 383(5): 1181-94.
48. Teng B, Burant CF, Davidson NO. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993; 260(5115): 1816-9.
49. Lo CM, Nordskog BK, Nauli AM, et al. Why does the gut choose Apolipoprotein B48 but not B100 for chylomicron formation? Am J Physiol Gastrointest Liver Physiol 2007.
50. Linton MF, Farese RV, Jr., Young SG. Familial hypobetalipoproteinemia. J Lipid Res 1993; 34(4): 521-41.
51. Jones B, Jones EL, Bonney SA, et al. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet 2003; 34(1): 29-31.
52. Kuge O, Dascher C, Orci L, et al. Sar1 promotes vesicle budding from the endoplasmic reticulum but not Golgi compartments. J Cell Biol 1994; 125(1): 51-65.
53. Cefalu AB, Calvo PL, Noto D, et al. Variable phenotypic expression of chylomicron retention disease in a kindred carrying a mutation of the Sara2 gene. Metabolism 2010; 59(4): 463-7.
54. Silvain M, Bligny D, Aparicio T, et al. Anderson's disease (chylomicron retention disease): a new mutation in the SARA2 gene associated with muscular and cardiac abnormalities. Clin Genet 2008; 74(6): 546-52.
55. Siddiqi SA, Gorelick FS, Mahan JT, Mansbach CM, 2nd. COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the pre-chylomicron transport vesicle. J Cell Sci 2003; 116(Pt 2): 415-27.
56. Sabesin SM, Frase S. Electron microscopic studies of the assembly, intracellular transport, and secretion of chylomicrons by rat intestine. J Lipid Res 1977; 18(4): 496-511.
57. Dixon JB. Mechanisms of chylomicron uptake into lacteals. Ann N Y Acad Sci 2010; 1207(Suppl 1): E52-7.
58. Dumont AE, Libby N. Thoracic duct lymph in a patient with chylous ascites and a carcinoid tumor. Lymphology 1989; 22(4): 199-201.
59. Brown HS, Halliwell M, Qamar M, Read AE, Evans JM, Wells PN. Measurement of normal portal venous blood flow by Doppler ultrasound. Gut 1989; 30(4): 503-9.
60. Trevaskis NL, Charman WN, Porter CJ. Correction to targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?. Mol Pharm 2011; 8(6): 2484.
61. Trevaskis NL, Charman WN, Porter CJ. Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? Mol Pharm 2010; 7(6): 2297-309.
62. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002; 41(10): 751-90.
63. Plusquellec Y, Arnaud R, Saivin S, et al. Enterohepatic recirculation of the new antihypertensive drug UP 269-6 in humans. A possible model to account for multiple plasma peaks. Arzneimittelforschung 1998; 48(2): 138-44.
64. Jandacek RJ, Tso P. Enterohepatic circulation of organochlorine compounds: a site for nutritional intervention. J Nutr Biochem 2007; 18(3): 163-7.
65. Trevaskis NL, Porter CJ, Charman WN. Bile increases intestinal lymphatic drug transport in the fasted rat. Pharm Res 2005; 22(11): 1863-70.
66. Luchoomun J, Hussain MM. Assembly and secretion of chylomicrons by differentiated Caco-2 cells. Nascent triglycerides and preformed phospholipids are preferentially used for lipoprotein assembly. J Biol Chem 1999; 274(28): 19565-72.
67. Ichihashi T, Nagasaki T, Takagishi Y, Yamada H. A quantitative concept of the mechanism of intestinal lymphatic transfer of lipophilic molecules. Pharm Res 1994; 11(4): 508-12.
68. Hauss DJ, Mehta SC, Radebaugh GW. Targeted lymphatic transport and modified systemic distribution of Cl-976, a lipophilic lipid-regulator drug, via a formulation approach. Int J Pharm 1994; 108: 85-93.
69. Trevaskis NL, McEvoy CL, McIntosh MP, et al. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). Pharm Res 2010; 27(5): 878-93.
70. Takada K, Yoshimura H, Shibata N, et al. Effect of administration route on the selective lymphatic delivery of cyclosporin A by lipidsurfactant mixed micelles. J Pharmacobiodyn 1986; 9(2): 156-60.
71. Ueda CT, Lemaire M, Gsell G, Nussbaumer K. Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats. Biopharm Drug Dispos 1983; 4(2): 113-24.
72. Ichihashi T, Kinoshita H, Takagishi Y, Yamada H. Intrinsic lymphatic partition rate of mepitiostane, epitiostanol, and oleic acid absorbed from rat intestine. Pharm Res 1991; 8(10): 1302-6.
73. Nankervis R, Davis SS, Day NH, Shaw PN. Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle. Int J Pharm 1996; 130: 57-64.
74. Porter CJ, Charman SA, Humberstone AJ, Charman WN. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J Pharm Sci 1996; 85(4): 357-61.
75. Caliph SM, Charman WN, Porter CJ. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and noncannulated rats. J Pharm Sci 2000; 89(8): 1073-84.
76. Khoo SM, Porter CJH, Edwards GA, Charman WN. Intestinal lymphatic transport is the primary route for halofantrine after oral postprandial administration. Pharm Sci 1999; 1: S-624.
77. Myers RA, Stella VJ. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int J Pharm 1992; 80: 511-62.
78. Neilson PB, Mullertz A, Norling T, Kristensen HG. Comparison of the lymphatic transport of a lipophilic drug from vehicles containing a-tocopherol and/or triglycerides in rats. J Pharm Pharmacol 2001; 53: 1439-45.
79. Ichihashi T, Kinoshita H, Takagishi Y, Yamada H. Effect of oily vehicles on absorption of mepitiostane by the lymphatic system in rats. J Pharm Pharmacol 1992; 44(7): 560-4.
80. Kwei GY, Novak LB, Hettrick LH, et al. Lymphatic uptake of MK-386, a sterol 5a-reductase inhibitor, from aqueous and lipid formulations. Int J Pharm 1998; 164: 37-44.
81. Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 1998; 87(2): 164-9.
82. Liu HX, Adachi I, Horikoshi I, Ueno M. Mechanism of promotion of lymphatic drug absorption by milk fat globule membrane. Int J Pharm 1995; 118: 55-64.